Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | EVP, Chief Financial Officer | March 02, 2023 | March 06, 2023 |
| GE HealthCare Technologies Inc.GEHC · Entity 1711 | Chief Financial Officer | May 01, 2026 | May 01, 2026 |
| Zoetis Inc.ZTS · Entity 679 | EVP, CFO & COO | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 177,899 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Tax withholding · Disposed 1,061 · Balance 177,899 F1: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 2, 2023 from the settlement of vested restricted stock units granted on March 2, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 2, 2023 from the settlement of vested restricted stock units granted on March 2, 2022.
GE HealthCare Technologies Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 87,471 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Purchase · Acquired 3,310 · Balance 87,471 F1: The price reported represents the weighted average price of shares purchased. These shares were purchased in multiple transactions at prices ranging from $60.59 to $60.60, inclusive. The Reporting Person undertakes to provide to GE HealthCare Technologies Inc. ("GE HealthCare"), any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average price of shares purchased. These shares were purchased in multiple transactions at prices ranging from $60.59 to $60.60, inclusive. The Reporting Person undertakes to provide to GE HealthCare Technologies Inc. ("GE HealthCare"), any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Zoetis Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 81,063 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 81,063 · Balance 81,063 F1: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2: Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock. F3: One-third of the total number of RSUs will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, August 31, 2026; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Notwithstanding the foregoing, if the Reporting Person's employment with the Company is terminated without Cause (as defined in the Zoetis Executive Severance Plan) prior to the first vesting date, one-third of the RSUs will accelerate and vest as of the date of such termination and will be settled in accordance with the applicable award agreement. F4: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs").
F2: Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock.
F3: One-third of the total number of RSUs will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, August 31, 2026; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Notwithstanding the foregoing, if the Reporting Person's employment with the Company is terminated without Cause (as defined in the Zoetis Executive Severance Plan) prior to the first vesting date, one-third of the RSUs will accelerate and vest as of the date of such termination and will be settled in accordance with the applicable award agreement.
F4: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2018 Filed Mar 7, 2018 22:35 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 2,497 | $66.85 | $166,924.45 |
DisclosureSEC source: 0001593636-18-000003 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,345 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of partial vesting of restricted stock granted on March 3, 2015.. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:20 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 97,093 | $0.00 Strike: $66.31 | $0.00 |
DisclosureSEC source: 0001593636-18-000002 · edgar.xml · derivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,093 Underlying: Common Stock, $1 par value · 97,093 shares Expires 2028-03-01 F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on the first anniversary of the date of the grant. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 22:30 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 5,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-18-000001 · edgar.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,842 F2 · kind: Represents shares earned from the performance share unit award granted on March 2, 2017 pursuant to the Equity Plan adopted by Baxter as of such date. The award provides that fifty percent of the performance share units are earned based on the Baxter's Adjusted Operating Margin (OM) performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares earned based on Baxter's OM, as assessed from January 1, 2017 to December 31, 2017. These shares are scheduled to vest after the end of the relevant three-year performance period (which runs from January 1, 2017 through December 31, 2019). Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 22:30 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 8,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-18-000001 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,331 F1 · kind: Represents shares earned from the performance share unit award granted on March 3, 2016 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date. The award provides that fifty percent of the performance share units are earned based on the Baxter's Adjusted Operating Margin (OM) performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares earned based on Baxter's OM, as assessed from January 1, 2017 to December 31, 2017. These shares are scheduled to vest after the end of the relevant three-year performance period (which runs from January 1, 2016 through December 31, 2018). Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:09 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 5,965 | $62.18 | $370,903.70 |
DisclosureSEC source: 0001593636-17-000005 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,467 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of the final vesting of restricted stock granted on September 2, 2014. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:45 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-17-000004 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,433 F1 · shares: The reporting person received a grant of 75,000 restricted stock units which are scheduled to vest on September 1, 2021, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2015 Incentive Plan. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 21:12 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 2,633 | $50.91 | $134,046.03 |
DisclosureSEC source: 0001593636-17-000003 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · CVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,325 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of partial vesting of restricted stock granted on March 3, 2015. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 21:33 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 117,647 | $0.00 Strike: $50.77 | $0.00 |
DisclosureSEC source: 0001593636-17-000002 · edgar.xml · derivative · entry 1 SACCARO JAMES · CIK 0001593636 · CVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,647 Underlying: Common Stock,$1 par value · 117,647 shares Expires 2027-03-02 F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on the first anniversary of the date of the grant. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:26 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 9,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-17-000001 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · CVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,958 F1 · kind: Represents shares earned from the performance share unit award granted on March 3, 2016 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date. The award provides that fifty percent of the performance share units are earned based on the Baxter's Adjusted Operating Margin (OM) performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares earned based on Baxter's OM, as assessed from January 1, 2016 to December 31, 2016. These shares are scheduled to vest after the end of the relevant three-year performance period (which runs from January 1, 2016 through December 31, 2018). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.